Metraipolis › archive › dc_ba2c501fa788

Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections — Europe PMC PMID:41487519

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41487519
DOI
10.3389/fphar.2025.1713471
License (as archived)
solo-consultazione
Archived
2026-11-07T13:20:02.639Z
SHA-256 of the archived text
82031a098f856be5ecd24b9f7217851208d2993977abc5dc5e94ffbfd0416712
Stable URL of this page
https://metraipolis.com/documento/dc_ba2c501fa788

How to cite

Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections — Europe PMC PMID:41487519 — Europe PMC (en), https://europepmc.org/article/MED/41487519 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ba2c501fa788 (Metraipolis archive dc_ba2c501fa788, sha256 82031a098f856be5ecd24b9f7217851208d2993977abc5dc5e94ffbfd0416712)
BibTeX
@misc{dcba2c501fa788,
  title = {Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections — Europe PMC PMID:41487519},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41487519},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ba2c501fa788; sha256 82031a098f856be5ecd24b9f7217851208d2993977abc5dc5e94ffbfd0416712},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41487519. Agents can read the archived copy with the MCP tool read_document.